Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17903914 | 0.92 | KCNH2 (0.43) | MEN1KMT2AMAPTCYP2C9KCNH2 | |
| SCHEMBL16264478 | 0.90 | CYP2C9 (0.52) | MEN1KMT2AMAPTGSK3BCYP2C9 | |
| SCHEMBL16264377 | 0.81 | CYP2C9 (0.54) | MEN1KMT2AMAPTCYP2C9KCNH2 | |
| SCHEMBL16264365 | 0.81 | CYP2C9 (0.54) | MEN1KMT2AMAPTCYP2C9KCNH2 | |
| SCHEMBL16264633 | 0.81 | CYP2C9 (0.45) | MAPTGSK3BCYP2C9KDM4E | |
| SCHEMBL16264345 | 0.81 | MAPT (0.49) | MEN1KMT2AMAPTGSK3BCYP2C9 | |
| SCHEMBL16264381 | 0.80 | CYP2C9 (0.51) | MEN1KMT2AMAPTGSK3BCYP2C9 | |
| SCHEMBL17903916 | 0.80 | CYP2C9 (0.50) | MEN1KMT2AMAPTGSK3BCYP2C9 | |
| SCHEMBL17903632 | 0.79 | CYP2C9 (0.51) | MEN1KMT2AMAPTCYP2C9KCNH2 | |
| SCHEMBL17905898 | 0.79 | CYP2C9 (0.51) | MEN1KMT2AMAPTGSK3BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-07-07 | — | — | US | disclosed |
| WO-2014190199-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194299-A1 | COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS | FNTB, PGLS, EP300 | MEN1 3943/4885KMT2A 3579/4885MAPT 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.